Země: Malajsie
Jazyk: angličtina
Zdroj: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
Human coagulation factor VIII; Von Willebrand Factor
DKSH MALAYSIA SDN. BHD.
Human coagulation factor VIII; Von Willebrand Factor
1 Vials
CSL Behring GmbH
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_ _ _ HAEMATE P _®_ POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION Human Coagulation Factor VIII/ Human Von Willebrand Factor (250IU FVIII / 600IU VWF, 500IU FVIII / 1200IU VWF, 1000IU FVIII / 2400IU VWF) Page 1 WHAT IS IN THIS LEAFLET 1. What Haemate P ® is used for 2. How Haemate P ® works 3. Before you use Haemate P ® 4. How to use Haemate P ® 5. While you are using Haemate P ® 6. Side effects 7. Storage and Disposal of Haemate P ® 8. Product Description 9. Manufacturer and Product Registration Holder 10. Date of revision WHAT HAEMATE P ® IS USED FOR Haemate P ® is supplied as powder and solvent. The made up solution is to be given by injection or infusion into a vein. Haemate P ® is made from human plasma (this is the liquid part of the blood) and it contains human von Willebrand factor and human coagulation factor VIII. As Haemate P ® contains both FVIII and VWF, it is important to know which factor you most need. If you have haemophilia A your doctor will prescribe you Haemate P ® with the number of units of FVIII specified. If you have VWD your doctor will prescribe you Haemate P ® with the number of units of VWF specified. HOW HAEMATE P ® WORKS Von Willebrand disease (VWD) Haemate P ® is used for the prevention and treatment of bleedings or surgical bleeding caused by the lack of von Willebrand factor, when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated. Haemophilia A (congenital factor VIII deficiency) Haemate P ® is used to prevent or to stop bleedings caused by the lack of factor VIII in the blood. It may also be used in the management of acquired factor VIII deficiency and for treatment of patients with antibodies against factor VIII. BEFORE YOU USE HAEMATE P ® _- When you must not use it _ Tell your doctor if you: • are hypersensitive (allergic) to human von Willebrand Factor or human coagulation factor VIII or any of the other ingredients of Haemate P ® • are allergic to any medicine or food. _- Přečtěte si celý dokument
CSL BEHRING CCDS HUMAN COAGULATION FVIII + HUMAN VWF, HAEMATE ® VERSION 11.0 REVISION DATE 30-AUG-2019 Clean_GRDC_67ad03 Page 2 of 17 1. NAME OF THE MEDICINAL PRODUCT Haemate P _ _ Powder and solvent for solution for injection or infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial _Haemate P 250IU FVIII/ 600IU VWF _ contains nominally: 250 IU human coagulation factor VIII (FVIII). 600 IU human von Willebrand factor (VWF). After reconstitution with 5ml the solution contains 50 IU/ml of FVIII and 120 IU/ml of VWF. One vial _Haemate_ _ _ _P_ _500 IU FVIII /1200 IU VWF _ contains nominally: _ _ 500IU human coagulation factor VIII (FVIII). 1200 IU human von Willebrand factor (VWF). After reconstitution with 10 ml the solution contains 50 IU/ml of FVIII and 120 IU/ml of VWF. One vial _Haemate_ _ _ _P 1000 IU FVIII /2400 IU VWF _ contains nominally: _ _ 1000IU human coagulation factor VIII (FVIII). 2400 IU human von Willebrand factor (VWF). After reconstitution with 15 ml the solution contains 66.6 IU/ml of FVIII and 160 IU/ml of VWF. The FVIII potency (IU) is determined using the European Pharmacopoeia chromogenic assay. The specific FVIII activity of _Haemate P_ is approximately 2 - 6 IU of FVIII/mg protein The VWF potency (IU) is measured according to ristocetin cofactor activity (VWF:RCo) compared to the International Standard for von Willebrand factor concentrate (WHO)The specific VWF activity of _ Haemate P_ is approximately 5 - 17 IU of VWF:RCo/mg protein. _Haemate P_ is produced from the plasma of human donors. Excipient with known effect: Sodium: _Haemate P 250 IU FVIII/600 IU VWF and Haemate P 500 IU FVIII / 1200 IU VWF _ – approximately 113 mmol/l (2.6 mg/ml) _Haemate_ _ _ _P_ _1000 IU FVIII /2400 IU VWF_ – approximately 150 mmol/l (3.5 mg/ml) _ _ For the full list of excipients, see section 6.1 CSL BEHRING CCDS HUMAN COAGULATION FVIII + HUMAN VWF, HAEMATE ® VERSION 11.0 REVISION DATE 30-AUG-2019 Clean_GRDC_67ad03 Page 3 of 17 3. PHARMACEUTICAL FORM Powder and solvent for solution for injectio Přečtěte si celý dokument